

Table 1 General study characteristics

General study data		HIV(+) patients					HIV(-) patients					Treatment scheme			
Author	Years	Prevalence	Genotyping	Total patients	Total available	Availability %	Total	Endogenous	Exogenous	Total	Endogenous	Exogenous	Treatment scheme	% Cred	Dots
Banda [11]	1995														
Italy / Prospective	1999 (5)	13	1,2	2127	3232	100	488	109	1	1639	22	184	No specified (6 months HRES)	6NE	Ec NE
Charalambous [12]	1999														
South Africa / Prospective	2001 (2.5)	589	1	609	5016	28	311	384	10	197	12	11	No specified	NE	Yes
Crampin [13]	1995														
Malawi- / Prospective	2003 (7.5)	349	1	584	5339	74	344	31	11	240	22	111	Before 1997: 2SHR/6TH Since 1997-2001: 1STH/11TH After 2001: 2HRZ/EH	NE	Yes
Hawken [14]	1989														
Kenya / Prospective	1991 (2)	245.5*	1	196	113	27	58	102	1	138	1	00	STH/TH 1STH/11TH SHRZ/TH 1HRZS/1HRZ/3TH	70%	No, control led adherence measured in visits and isoniazid metabolites in urine
Jasmer	1995														
Canada / Prospective	2004 (10)	8.2	1,2	1244	7975	95	240	1514	14	1004	60	582	TBTC22: 2HRZE/4Rifapentin H1 TBTC23: HEZRifabutina/4H2Rifabutina.	NE	Yes
Sonnenberg [16]	1995														
South Africa / Prospective	1998 (4)	428	1	326	6539	60	151	1418	13	175	24	171	2HRZE/4HR	NE	Yes
Johnson [17]	1993														
Uganda	1994	479	1	224	184	21	203	172	0	21	1	10	2HRZE/6HR	VIH (+)	No, Auto-75% admini

Study	Year	Design	Sample Size	Interventions	Outcomes	Adverse Effects	Other	Notes												
Luzze [18]	1993	Prospective	396	1	170	170	97	57	95	31	20	45	12	74	75	34	6	2HRZE/4HR 1598 Patients 2HRZE/6HE 103 Patients	91	VIH stered (-) with 84% monthly follow-up No, controlled monthly until its finalization and subsequently every 3 months HIV (+) the first phase was observed and the second phase was taken weekly HIV (-) non specified
Narayanan [19]	1999	Prospective	38	1,2,3	NE	69	48	69	30	64	4	3	22	NE	25	21	2	HIV+ : 2HRZE3/4HR3 or 2HRZE3/7HR3 HIV-: 2HRZE3/4HR3 11 Patients 3HRZO/1HRO3 or 3HRZO/2HRO3 12 Patients	79%	VIH the second phase was taken weekly HIV (-) non specified
Nahid [20]	1990	Retrospective	11	1	700	16	11	68	26	41	3	13	0	43	63	3	0	No specified	79%	69% of patients
Nettles [21]	1990	Retrospective	10	1	361	14	9	64	10	25	5	5	0	25	94	4	0	15 daily doses of HRZE/ 6 weeks of HRZE2/HR2	NE	Yes
Millet [22]	2003	Retrospective	24	1,2,3	971	13	6	46	88	89	2	2	0	83	4	1	3	No specified	65%	No, only 19% of patient
Cacho [24]	1992	Prospective	2	1,3	366	8	8	10	0	NE	4	4	0	NE	4	3	1	2HRZ/4HR 2HRZE/4HR	0	NE NE

